Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed Inc.’s Chairman and CEO, Michael J. Farrell, reported changes in beneficial ownership of the company’s common stock. The transactions, conducted under a pre-established Rule 10b5-1 plan, involved the acquisition and subsequent sale of shares, reflecting strategic financial management by the company’s leadership. These transactions may influence investor perceptions and highlight the company’s ongoing commitment to aligning executive interests with shareholder value.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of medical equipment related to sleep disorders, respiratory care, and other chronic diseases. The company is known for its innovative solutions in sleep apnea treatment and has a significant market presence in the global healthcare sector.
Average Trading Volume: 1,245,947
Technical Sentiment Signal: Buy
Current Market Cap: A$56.52B
See more data about RMD stock on TipRanks’ Stock Analysis page.